+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Bromocriptine-lnduced Blockade of Pregnancy Affects Sleep Patterns in Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We previously reported a marked enhancement of nocturnal sleep in pregnant and pseudopregnant rats and suggested a possible involvement of prolactin (PRL) in the modulation of sleep during pregnancy. In the present study, the release of PRL was blocked by a dopamine agonist, bromocriptine (CB-154), and time-course changes in sleep were analyzed in pregnant rats. After pregnancy was induced by fertile mating with males (Day 1), rats (n = 5) were injected with 1 mg of CB-154 subcutaneously 3 h before the onset of darkness for a 3-day period (Days 1–3 or 6–8). Electroencephalogram and electromyo-gram for evaluating the state of sleep and wakefulness were monitored continuously up to the reappearance of an estrous cycle in the treated rats. The CB-154 treatment resulted in abortion in all rats and suppressed the pregnancy-associated nocturnal increase in non-rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep (REMS). The CB-154 treatment also decreased the diurnal amount of NREMS significantly. The sleep-suppressing effect of CB-154 on Days 6-8 was induced more promptly than that on Days 1-3. In the night of proestrus following the termination of pregnancy (Day 4 or Day 12), both NREMS and REMS decreased to the baseline level observed at prepregnant proestrus. Thus, our results indicated that CB-154 neutralized the pregnancy-associated sleep changes, which might be due to the inhibition of the PRL release. It is suggested that PRL is at least partially responsible for the regulation of sleep during pregnancy.

          Related collections

          Author and article information

          S. Karger AG
          19 March 1997
          : 3
          : 4
          : 219-226
          Institute for Medical and Dental Engineering, Tokyo Medical and Dental University, Tokyo, Japan
          97274 Neuroimmunomodulation 1996;3:219–226
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article